Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co.

Odyssey Therapeutics (NASDAQ:ODTX) had its price objective lifted by JPMorgan Chase & Co. from $26.00 to $29.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 32.12% from the company’s previous close.

Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating on the stock. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Wedbush began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective for the company. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Finally, TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.00.

Odyssey Therapeutics Stock Performance

Shares of NASDAQ ODTX traded up $0.40 during mid-day trading on Friday, hitting $21.95. The company had a trading volume of 20,771 shares, compared to its average volume of 313,121. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $22.26. The business’s 50-day simple moving average is $17.78.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Odyssey Therapeutics will post -4.89 EPS for the current year.

Insider Buying and Selling at Odyssey Therapeutics

In other Odyssey Therapeutics news, Director Shelley Chu purchased 11,111 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the transaction, the director directly owned 11,111 shares in the company, valued at approximately $199,998. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Nan (Ln) Li purchased 1,111,111 shares of the business’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 3,066,666 shares of company stock worth $55,199,988 in the last quarter.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.